Prüftechnik ShaftAlign Touch Laser Alignment System Enables Technicians to Quickly and Precisely Align the Majority of Standard Machines
Prüftechnik, a division of Fluke Reliability, introduces the ShaftAlign Touch laser alignment system, a new digital solution that exceeds the capabilities of conventional tools and delivers greater speed and accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005134/en/
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. (Photo: Business Wire)
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. Prüftechnik Adaptive Alignment systems, such as the ShaftAlign Touch, automatically eliminate user errors and low-quality measurement points by adapting to the asset, the alignment situation, and the technician who is performing the job. Cloud-compatible software allows newer technicians to share measurements with more experienced colleagues or consultants — inside the plant or across the globe — to complete a job.
“ShaftAlign Touch is a significant improvement over conventional shaft alignment measurement equipment and basic laser systems in the market,” said Ankush Malhotra, vice president and general manager of Fluke Reliability. “With its intuitive computer-based, guided user interface, single-laser technology, and cloud-transfer capabilities, ShaftAlign Touch, sets a new benchmark for solving alignment issues at an unbeatable price/performance ratio.”
ShaftAlign Touch delivers:
- High performance and precise results — ShaftAlign Touch leverages single-laser technology to provide high-precision, high-performance alignment measurements.
- Quick setup and intuitive user interface — its swift setup and tablet-like, intuitive guided user interface make it more user-friendly than any of the conventional alignment measurement methods.
- Ability to share data via the cloud — technicians can leverage its integrated Wi-Fi cloud solution to easily transfer measurement data from the ShaftAlign Touch handheld device to the ARC 4.0 software.
ShaftAlign Touch is the latest addition to the family of Prüftechnik Adaptive Alignment laser systems. Adaptive Alignment is a combination of software and hardware that enables maintenance and reliability teams to adjust to most any horizontal, angular, or vertical alignment challenge. With Adaptive Alignment solutions, work is completed faster, results are more accurate, and team capabilities are better utilized compared to other market solutions.
For more information on the Prüftechnik ShaftAlign Touch, visit https://www.pruftechnik.com/en-US/Products-and-Services/Alignment-Systems-for-Rotating-Machinery/Shaft-Alignment/Shaft-Alignment-Systems/SHAFTALIGN-touch/.
Prüftechnik is a worldwide provider of maintenance technology with a comprehensive product, service, and training program tailored to the needs of maintenance experts in shaft alignment, vibration analysis, condition monitoring, and destruction-free testing. Many manufacturing companies worldwide trust its solutions for reliable and condition-based maintenance of rotating machines. For more information, visit https://www.pruftechnik.com.
About Fluke Reliability
Fluke Reliability offers reliability and maintenance teams the tools, software, and services they need to optimize asset performance. Home to three powerful iconic brands – Prüftechnik, eMaint, and Fluke Connect – Fluke Reliability serves more than 70,000 customers worldwide with a relentless dedication to quality, innovation, and service. Its products inform customers on the health of their assets, and its software and services drive better maintenance decisions – improving productivity, driving uptime, and reducing costs. For more information, visit https://www.accelix.com.
FLUKE is a registered trademark of Fluke Corporation. For more information, visit the Fluke website.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom